Here with the trade day takeaways is Yahoo Finances Jared Blickery. Jared, >> thank you. Josh, it is a wrap for January.So, let's go over the numbers. And what a crazy end to the month. I will say the S&P 500 eaked out a gain for the week.So, it snaps a I believe a two-eek losing streak. But here are some of the major indices that I'm watching here. Now, in the very left, we got the socks.That's a Philly chip index. That's up 12.9% in January. That year-to date covers us monthto date as well.Then the S&P 60 ...

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of New Era Energy & Digital, Inc. due to allegations of materially misleading business information issued by the company [1] Group 1: Legal Action and Investor Rights - Investors who purchased New Era Energy & Digital securities may be entitled to compensation through a contingency fee arrangement, with a class action being prepared to recover investor losses [2] - To join the prospective class action, investors can submit a form or contact the law firm directly for more information [2] Group 2: Company Performance and Allegations - New Era Energy & Digital's stock fell 6.9% on December 12, 2025, following a report from Fuzzy Panda Research that criticized the company's financial practices, alleging excessive spending on stock promotions compared to operational costs [3] - The report claimed that the CEO has a history of mismanaging penny stock companies over the past 20 years [3] Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked highly for the number of settlements [4] - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone, and has received recognition for its attorneys [4]

Company Performance - Main Street Capital (MAIN) closed at $63.80, reflecting a -1.21% change from the previous day, underperforming the S&P 500's loss of 0.43% [1] - Over the past month, shares of Main Street Capital have appreciated by 6.94%, significantly outperforming the Finance sector's gain of 0.35% and the S&P 500's gain of 0.89% [1] Upcoming Earnings - The upcoming earnings release is scheduled for February 26, 2026, with projected earnings of $1.06 per share, indicating a year-over-year growth of 3.92% [2] - The consensus estimate anticipates revenue of $140.81 million, reflecting a 0.26% increase from the same quarter last year [2] Annual Forecast - For the entire year, the Zacks Consensus Estimates forecast earnings of $4.19 per share and revenue of $561.66 million, showing changes of +2.44% and 0% respectively compared to the previous year [3] Analyst Estimates - Recent changes to analyst estimates for Main Street Capital are important as they reflect the shifting dynamics of short-term business patterns, with upward revisions indicating analysts' positive outlook on the company's operations [4] - The Zacks Rank system, which incorporates these estimate changes, provides a practical rating system for investors [5] Zacks Rank and Valuation - Main Street Capital currently holds a Zacks Rank of 3 (Hold), with the consensus EPS estimate remaining unchanged over the last 30 days [6] - The company is trading at a Forward P/E ratio of 15.89, which is a premium compared to the industry average Forward P/E of 8.8 [7] Industry Context - The Financial - SBIC & Commercial Industry, part of the Finance sector, has a Zacks Industry Rank of 97, placing it in the top 40% of over 250 industries [7] - The Zacks Industry Rank assesses the strength of industry groups, with top-rated industries outperforming the bottom half by a factor of 2 to 1 [8]

Company Performance - Medpace's stock closed at $582.48, reflecting a decrease of -1.79% from the previous day, underperforming compared to the S&P 500's daily loss of 0.43% [1] - Over the last month, Medpace's shares have increased by 5.59%, outperforming the Medical sector's loss of 2.36% and the S&P 500's gain of 0.89% [1] Upcoming Earnings - Medpace is set to disclose its earnings on February 9, 2026, with analysts expecting earnings of $4.18 per share, indicating a year-over-year growth of 13.9% [2] - The consensus estimate for revenue is projected at $681.17 million, representing a growth of 26.94% compared to the same quarter last year [2] Full Year Projections - For the full year, Zacks Consensus Estimates project earnings of $14.8 per share and revenue of $2.5 billion, reflecting changes of +17.18% and 0% respectively from the prior year [3] - Recent changes to analyst estimates indicate a positive outlook for Medpace, as upward revisions are often seen as a sign of optimism regarding business trends [3] Valuation Metrics - Medpace has a Forward P/E ratio of 35.67, which is a premium compared to the industry average Forward P/E of 15.73 [6] - The company has a PEG ratio of 1.99, compared to the Medical Services industry's average PEG ratio of 1.77 [6] Industry Context - The Medical Services industry, which includes Medpace, ranks 178 in the Zacks Industry Rank, placing it in the bottom 28% of over 250 industries [7] - The Zacks Industry Rank evaluates the performance potential of industry groups, indicating that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [7]

Company Performance - Pacific Biosciences of California (PACB) closed at $2.26, reflecting a -4.64% change from the previous day, underperforming the S&P 500's daily loss of 0.43% [1] - Over the past month, PACB shares have gained 26.74%, while the Medical sector has lost 2.36% and the S&P 500 has gained 0.89% [1] Earnings Estimates - The company is expected to release its earnings on February 12, 2026, with projected earnings per share (EPS) of -$0.19, indicating a 5% increase from the same quarter last year [2] - Full-year Zacks Consensus Estimates predict earnings of -$1.89 per share and revenue of $0 million, representing year-over-year changes of -127.71% and 0%, respectively [3] Analyst Insights - Recent changes to analyst estimates for Pacific Biosciences should be monitored, as positive revisions are often seen as a good sign for business outlook [3] - The Zacks Rank system, which includes estimate changes, currently ranks Pacific Biosciences at 3 (Hold), with no changes in the Zacks Consensus EPS estimate over the past month [5] Industry Context - The Medical - Instruments industry, which includes Pacific Biosciences, has a Zacks Industry Rank of 88, placing it in the top 36% of over 250 industries [6] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [6]

Core Viewpoint - A class action lawsuit has been filed against Ramaco Resources, Inc. due to allegations of misleading statements regarding the company's Brook Mine operations, which reportedly did not commence significant mining activity as claimed [1][4]. Group 1: Lawsuit Details - The lawsuit is filed in the United States District Court for the Southern District of New York, under the case caption Henning v. Ramaco Resources, Inc., and covers the period from July 31, 2025, to October 23, 2025 [1]. - The lawsuit claims violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, asserting that the defendants made materially false and misleading statements about the company's business and operations [1][4]. Group 2: Allegations Against Ramaco - Wolfpack Research published a report on October 23, 2025, alleging that Ramaco's Brook Mine was a "hoax" and that no active mining work had occurred since its groundbreaking in July [3]. - The report indicated that drone footage taken three months after the mine's opening showed no active work, contradicting the company's claims of progress [3]. - Following the report, Ramaco's stock price dropped by $3.81, or 9.6%, closing at $36.01 per share on October 23, 2025, with unusually high trading volume [3]. Group 3: Misleading Statements - The complaint alleges that the defendants failed to disclose critical information, including the lack of significant mining activity at the Brook Mine and the overstated development progress [4]. - It is claimed that the positive statements made by the defendants regarding the company's operations were materially misleading and lacked a reasonable basis [4].

Core Points - Permex Petroleum Corporation has received a Notice of Default from holders of its secured convertible debentures, which have an aggregate principal of $4,276,389 and an interest rate of 10% per annum [1][2] - The Company failed to make any payments on the Debentures by the due date of November 2, 2025, and has been demanded to pay all outstanding indebtedness by February 18, 2026, or face potential repossession of collateral [2] - Permex has not filed its audited annual financial statements for the year ended September 30, 2025, by the regulatory deadline of January 28, 2026 [3]

Core Insights - Verizon Communications reported its strongest subscriber gains in years, leading to a significant increase in stock price by over 11% [1][2]. Subscriber Growth - In the fourth quarter, Verizon achieved its highest quarterly net customer additions since 2019, gaining 616,000 postpaid phone subscribers and 372,000 broadband subscribers [2]. Competitive Strategy - New CEO Dan Schulman aims to strengthen Verizon's market position, stating that the company will no longer be an easy target for competitors like AT&T and T-Mobile [3]. Financial Performance - Verizon's total operating revenue for the fourth quarter rose by 2% year over year to $36.4 billion, while adjusted earnings per share slightly declined by less than 1% to $1.09, surpassing Wall Street's expectations of $1.06 [5]. Future Outlook - The company generated $20.1 billion in free cash flow in 2025, with management projecting a growth of approximately 7% to at least $21.5 billion in 2026, supported by anticipated retail postpaid phone net additions of 750,000 to 1 million [6].

Core Points - Rosen Law Firm is reminding investors who purchased CoreWeave, Inc. securities between March 28, 2025, and December 15, 2025, of the lead plaintiff deadline on March 13, 2026 [1] - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] Class Action Details - A class action lawsuit has been filed against CoreWeave, alleging that the company made false and misleading statements regarding its ability to meet customer demand and the risks associated with reliance on a single third-party data center supplier [4] - The lawsuit claims that these misstatements were likely to have a material negative impact on CoreWeave's revenue, leading to investor damages when the truth was revealed [4] Legal Representation - Investors are encouraged to select qualified legal counsel with a successful track record in securities class actions, as many firms may not have the necessary experience [3] - Rosen Law Firm has a history of significant recoveries for investors, including over $438 million in 2019 alone, and has been recognized for its leadership in securities class action settlements [3]

Core Viewpoint - The article discusses the expertise and background of Ernest Hoffman, a Crypto and Market Reporter for Kitco News, highlighting his extensive experience in market news and journalism [3]. Group 1 - Ernest Hoffman has over 15 years of experience in writing, editing, broadcasting, and producing for various media and cultural organizations [3]. - He began his career in market news in 2007, where he established a broadcast division that created the fastest web-based audio news service globally [3]. - Hoffman has a Bachelor's degree in Journalism from Concordia University [3].